- Previous Close
1.8720 - Open
1.7920 - Bid 1.8320 x --
- Ask 1.9260 x --
- Day's Range
1.7920 - 1.8460 - 52 Week Range
1.4860 - 5.5500 - Volume
2,500 - Avg. Volume
0 - Market Cap (intraday)
29.988M - Beta (5Y Monthly) -1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0600 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
www.acurxpharma.comRecent News: 3ZO.F
View MorePerformance Overview: 3ZO.F
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3ZO.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3ZO.F
View MoreValuation Measures
Market Cap
30.38M
Enterprise Value
24.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-132.22%
Return on Equity (ttm)
-346.94%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.73M
Diluted EPS (ttm)
-1.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
6.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.96M